Advertisement

Topics

Seattle Genetics Inc. Company Profile

21:52 EDT 21st October 2018 | BioPortfolio

Seattle Genetics is an innovative biotechnology company dedicated to improving the lives of people with cancer through novel antibody-based therapies. The company’s industry-leading antibody-drug conjugate (ADC) technology harnesses the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells. Seattle Genetics commercializes ADCETRIS® (brentuximab vedotin) for the treatment of several types of CD30-expressing lymphomas. The company is also advancing a robust pipeline of novel therapies for solid tumors and blood-related cancers designed to address significant unmet medical needs and improve treatment outcomes for patients. More information can be found at www.seattlegenetics.com and follow @SeattleGenetics on Twitter.


News Articles [611 Associated News Articles listed on BioPortfolio]

Unum gets $5mm investment from Seattle Genetics

Concurrent with closing its initial public offering, Unum Therapeutics Inc. sold partner Seattle Genetics Inc. 416,666 common shares at the IPO price of $12 each, for proceeds of $5mm. The companies t...

Seattle Genetics' Adcetris Has Potential to Change Treatment for T-Cell Lymphoma

Seattle Genetics and its development partner Takeda recently announced stellar Phase III data from its ECHELON-2 clinical trial of Adcetris for peripheral T-cell lymphoma. Clay Siegall, president and ...

Seattle Genetics Announces Adcetris Approval in Japan for Frontline Hodgkin Lymphoma

NewsSeattle Genetics and Takeda are jointly developing Adcetris.

Seattle Genetics completes enrolment in EV-201 trial

Seattle Genetics and Astellas Pharma have completed the enrolment of the first cohort of patients in the EV-201 trial, a...Read More... The post Seattle Genetics completes enrolment in EV-201 trial ap...

Seattle Genetics doses first patient in innovaTV 204 trial

Seattle Genetics has dosed the first patient in the innovaTV 204 trial, a Phase ll study examining the efficacy, safety...Read More... The post Seattle Genetics doses first patient in innovaTV 204 tri...

Seattle Genetics Reports Q2 Results, ADCETRIS Sales in Focus

Seattle Genetics reported its Q2 2018 financial results on Thursday (July 26), highlighting that it expects to report top-line data in Q4 from the phase 3 ECHELON-2 clinical trial in frontline CD30-ex...

Seattle Genetics Announces First Patient Dosed in Phase 2 Trial of Tisotumab Vedotin

Seattle Genetics (Nasdaq:SGEN) announced dosing of the first patient in the phase 2 innovaTV 204 clinical trial evaluating the efficacy, safety and tolerability of tisotumab vedotin as monotherapy fo...

Astellas and Seattle Genetics Receive FDA Breakthrough Therapy Designation for Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer

TOKYO and BOTHELL, Wash., March 26, 2018 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, "Astellas") and Seattle Genetics, Inc. (NASDAQ: SGEN) today announced t...

PubMed Articles [590 Associated PubMed Articles listed on BioPortfolio]

Validation of the Seattle angina questionnaire in women with ischemic heart disease.

Although the Seattle Angina Questionnaire (SAQ) has been widely used to assess disease-specific health status in patients with ischemic heart disease, it was originally developed in a predominantly ma...

Genetics is the logic of life (at least of mine).

I retrace my path from math to medicine to biochemistry to yeast genetics, my focus on infectious diseases of yeast and finally prions. My discovery of yeast prions relied on my particular focus on th...

Correction: A New Method for Estimating the Number of Undiagnosed HIV Infected Based on HIV Testing History, with an Application to Men Who Have Sex with Men in Seattle/King County, WA.

[This corrects the article DOI: 10.1371/journal.pone.0129551.].

Response to Nakaguma et al.

Hemoglobin Seattle detection based on low capillary oxygen saturation: First reported case in Japan.

Clinical Trials [370 Associated Clinical Trials listed on BioPortfolio]

Impact of Non-Commercialism Policy in Seattle Schools

This pilot study on the impact of a non-commercialism policy in Seattle schools will assess and evaluate obesity-related health outcomes of a real-life policy decision, recently voted on a...

Genetics Education: Preparing Physicians for the Future

This study examines the best way to teach genetics to family medicine residents. First year family medicine residents at the University of Toronto will be taught basic clinical genetics as...

Impact of Non-Commercialism Policy in Seattle Schools

This is a 3-year pilot study funded by National Institute of Health will assess and evaluate obesity-related health outcomes of a real-life policy decision, recently voted on and adopted b...

Experiences of Genetics Patients With Visible Abnormalities Who Facilitate Teaching in Genetics Clinics

This study will describe the experience of patients with visible physical abnormalities in the genetics clinic when they are involved in teaching others about their condition. Information ...

Reproducibility of Malaria Challenge in Healthy Volunteers

This is a prospective, single arm, single intervention safety and immunogenicity study in 6 healthy, malaria-naive adults, conducted to demonstrate the successful implementation of the wel...

Companies [253 Associated Companies listed on BioPortfolio]

AccessDNA, Inc.

AccessDNA is the leading online consumer resource for genetics. The company combines high-quality content about genetics with access to, and evaluation of, relevant testing, couns...

Ambry Genetics Corporation

Ambry Genetics is a privately held healthcare company with the industry’s most comprehensive suite of genetic testing solutions, benefiting 90% of all U.S. patients covered b...

Interleukin Genetics, Inc.

Interleukin Genetics, Inc. (OTCQB: ILIU) develops and markets a line of genetic tests under the Inherent Health® brand. The products empower individuals to prevent ce...

Seattle Genetics

Seattle Genetics, Inc. is a biotechnology company developing monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases. Our strategy is focused on advancing our portfolio...

Population Genetics

Harnessing The Power of Populations™ Population Genetics’ approach takes the process of genetic analysis one step further. It enables the elaboration and testing of distinct hypotheses...

More Information about "Seattle Genetics Inc." on BioPortfolio

We have published hundreds of Seattle Genetics Inc. news stories on BioPortfolio along with dozens of Seattle Genetics Inc. Clinical Trials and PubMed Articles about Seattle Genetics Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Seattle Genetics Inc. Companies in our database. You can also find out about relevant Seattle Genetics Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...


Corporate Database Quicklinks



Searches Linking to this Company Record